Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179337 | 0.81 | NCF1 (0.40) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL22142247 | 0.73 | L3MBTL1 (0.37) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL10236411 | 0.73 | L3MBTL1 (0.37) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL7589847 | 0.72 | NCF1 (0.37) | CYP2D6KCNH2HRH3 | |
| SCHEMBL11989609 | 0.72 | NCF1 (0.37) | CYP2D6KCNH2HRH3 | |
| SCHEMBL14093037 | 0.72 | NCF1 (0.37) | CYP2D6KCNH2HRH3 | |
| SCHEMBL24185791 | 0.70 | OPRL1 (0.38) | CYP2D6KCNH2HRH3 | |
| SCHEMBL107432 | 0.70 | OPRL1 (0.38) | CYP2D6KCNH2HRH3 | |
| SCHEMBL19703796 | 0.69 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL23682984 | 0.69 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C5AR1, C3AR1 | CYP2D6 748/4885KCNH2 2070/4885HRH3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.